vorinostat has been researched along with Body Weight in 5 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
Excerpt | Relevance | Reference |
---|---|---|
"Animals were dosed on Gestation Days 6-20 or 7-20, respectively, with litter/fetal parameters evaluated on GD 21 and 28, respectively." | 1.34 | Assessment of developmental toxicity of vorinostat, a histone deacetylase inhibitor, in Sprague-Dawley rats and Dutch Belted rabbits. ( Kerr, JS; Turner, KJ; Wise, LD, 2007) |
" Four compounds having an MTD > or = 100 mg/kg were selected for dose-response studies in the HCT116 xenograft model." | 1.32 | N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824). ( Atadja, P; Bair, KW; Bontempo, J; Cesarz, D; Chandramouli, N; Chen, R; Cheung, M; Cornell-Kennon, S; Dean, K; Diamantidis, G; France, D; Green, MA; Howell, KL; Kashi, R; Kwon, P; Lassota, P; Martin, MS; Mou, Y; Perez, LB; Remiszewski, SW; Sambucetti, LC; Sharma, S; Smith, T; Sorensen, E; Taplin, F; Trogani, N; Versace, R; Walker, H; Weltchek-Engler, S; Wood, A; Wu, A, 2003) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (60.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Remiszewski, SW | 1 |
Sambucetti, LC | 1 |
Bair, KW | 1 |
Bontempo, J | 1 |
Cesarz, D | 1 |
Chandramouli, N | 1 |
Chen, R | 1 |
Cheung, M | 1 |
Cornell-Kennon, S | 1 |
Dean, K | 1 |
Diamantidis, G | 1 |
France, D | 1 |
Green, MA | 1 |
Howell, KL | 1 |
Kashi, R | 1 |
Kwon, P | 1 |
Lassota, P | 1 |
Martin, MS | 1 |
Mou, Y | 1 |
Perez, LB | 1 |
Sharma, S | 1 |
Smith, T | 1 |
Sorensen, E | 1 |
Taplin, F | 1 |
Trogani, N | 1 |
Versace, R | 1 |
Walker, H | 1 |
Weltchek-Engler, S | 1 |
Wood, A | 1 |
Wu, A | 1 |
Atadja, P | 1 |
McGee-Lawrence, ME | 1 |
McCleary-Wheeler, AL | 1 |
Secreto, FJ | 1 |
Razidlo, DF | 1 |
Zhang, M | 1 |
Stensgard, BA | 1 |
Li, X | 1 |
Stein, GS | 1 |
Lian, JB | 1 |
Westendorf, JJ | 1 |
Casto, BC | 1 |
Pereira, MA | 1 |
Wise, LD | 2 |
Turner, KJ | 1 |
Kerr, JS | 2 |
Spence, S | 1 |
Saldutti, LP | 1 |
5 other studies available for vorinostat and Body Weight
Article | Year |
---|---|
N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).
Topics: Acetyltransferases; Acrylamides; Animals; Antineoplastic Agents; Body Weight; Cell Division; Dose-Re | 2003 |
Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts.
Topics: Acetylation; Animals; Biomarkers; Body Weight; Bone Marrow Cells; Bone Remodeling; Bone Resorption; | 2011 |
Prevention of mouse lung tumors by combinations of chemopreventive agents using concurrent and sequential administration.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Body Weight; Budesonide; Chemop | 2011 |
Assessment of developmental toxicity of vorinostat, a histone deacetylase inhibitor, in Sprague-Dawley rats and Dutch Belted rabbits.
Topics: Abnormalities, Drug-Induced; Animals; Body Weight; Dose-Response Relationship, Drug; Enzyme Inhibito | 2007 |
Assessment of female and male fertility in Sprague-Dawley rats administered vorinostat, a histone deacetylase inhibitor.
Topics: Administration, Oral; Animals; Body Weight; Dose-Response Relationship, Drug; Embryonic Development; | 2008 |